The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Promoting effective self-management programmes to improve COPD
Open accessAbstract
Objective: We aimed to validate the aggregated N-of-1 trials design using the case of mexiletine treatment in non-dystrophic myotonia. Background: In rare diseases it is difficult to achieve level 1 evidence of treatment efficacy due to small cohorts and clinical heterogeneity. With emerging treatments for rare diseases, validation of innovative trial designs is urgently needed. Design/Methods: We performed a series of aggregated, double-blind, randomized-controlled N-of-1-trials (mexiletine versus placebo) in 30 patients with non-dystrophic myotonia. The primary outcome measure was daily-reported muscle stiffness on a 1–9 scale, with higher scores indicating more impairment. Secondary outcomes included quality of life, myotonia and safety measures. A Bayesian hierarchical model combined individual N-of-1 trial results into the probability of reaching a clinically meaningful effect ( ≥ 0.75 difference on the primary outcome measure). To assess our trial design validity, we compared our results head-to-head with a previously conducted RCT. Eligibility criteria, treatment regimen, end-points and assessments were fully compatible between trials. Results: In 24 of the 27 patients who completed their N-of-1 trial, a clinically meaningful treatment effect was found. Mexiletine resulted in a mean muscle stiffness reduction of 3.06 (n=27, 95% credible interval 1.96–4.15). Adverse reactions included gastro-intestinal complaints (70%). The evidence that mexiletine reduces myotonia with a meaningful difference, with 95% probability, was reached after the first 11 consecutive patients. Meta-analysis of aggregated N-of-1 trials and RCT results showed absence of statistical heterogeneity (I2 = 0%) on the primary outcome measure. Secondary outcomes and adverse reactions profiles were comparable between trials. Conclusions: Our data show that aggregated N-of-1 trials produce a valid estimate of treatment effect at the group level. Compared to conventional designs, this trial approach seems promising with regard to efficiency and when dealing with patient heterogeneity. Furthermore, our data strengthen the evidence of mexiletine as a safe and effective treatment in non-dystrophic myotonia. Study Supported by: ZonMw, The Netherlands Organisation for Health Research and Development (Project number: 152002029) Disclosure: Dr. Stunnenberg has nothing to disclose. Dr. Raaphorst has nothing to disclose. Dr. Groenewoud has nothing to disclose. Dr. Statland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge, Acceleron, Regeneron, and Sanofi. Dr. Griggs has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serve on DSMB for PTC Therapeutics, Idera Pharma; consultant for Saretpta, Marathon, Strongbridge and Taro Pharma. Dr. Griggs has received personal compensation in an editorial capacity for Correspondence editor for Neurology. Dr. Griggs has received royalty, license fees, or contractual rights payments from Royalties from Marathon and PTC Pharmaceuticals. Dr. Griggs has received research support from Research support from Marathon, PTC. Dr. Woertman has nothing to disclose. Dr. Stegeman has nothing to disclose. Dr. Timmermans has nothing to disclose. Dr. Trivedi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi. Dr. Trivedi has received research support from Sanofi, CSL Behring. Dr. Matthews has nothing to disclose. Dr. Saris has nothing to disclose. Dr. Schouwenberg has nothing to disclose. Dr. Drost has nothing to disclose. Dr. van Engelen has nothing to disclose. Dr. van der Wilt has nothing to disclose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lorig, K. R., Sobel, D. S., Stewart, A. L., Brown, B. W., Bandura, A., Ritter, P., Gonzalez, V. M., Laurent, D. D., & Holman, H. R. (1999) · Medical Care · doi:10.1097/00005650-199901000-00003 · Cited by 2,261
Integrated care programmes for chronically ill patients: a review of systematic reviews
Ouwens, M. (2005) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzi016 · Cited by 606
Self-management education for patients with chronic obstructive pulmonary disease
Effing, T., Monninkhof, E. E., van der Valk, P. P. D. L. P. M., Zielhuis, G. G., Walters, E. H., van der Palen, J. J., & Zwerink, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub2 · Cited by 536
Cited by
Self management for patients with chronic obstructive pulmonary disease
Zwerink, M., Brusse-Keizer, M., van der Valk, P. D., Zielhuis, G. A., Monninkhof, E. M., van der Palen, J., Frith, P. A., & Effing, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub3 · Cited by 572
Self-citationLenferink, A., Brusse-Keizer, M., van der Valk, P. D., Frith, P. A., Zwerink, M., Monninkhof, E. M., van der Palen, J., & Effing, T. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011682.pub2 · Cited by 328
Hill, K., Goldstein, R. S., Guyatt, G. H., Blouin, M., Tan, W. C., Davis, L. L., Heels-Ansdell, D. M., Erak, M., Bragaglia, P. J., Tamari, I. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091784 · Cited by 262
Self-management interventions: Proposal and validation of a new operational definition
Jonkman, N. H., Schuurmans, M. J., Jaarsma, T., Shortridge-Baggett, L. M., Hoes, A. W., & Trappenburg, J. C. A. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.08.001 · Cited by 143
Korpershoek, Y. J. G., Vervoort, S. C. J. M., Trappenburg, J. C. A., & Schuurmans, M. J. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3545-4 · Cited by 87
Metadata
- Authors
- Bourbeau, J., & van der Palen, J.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2009-02-27
- Volume
- 33
- Issue
- 3
- Pages
- 461-463
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2123743870
- Cited by
- 167
- References
- 3
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promoting effective self-management programmes to improve COPD. https://app.cochat.ai/papers/10.1183/09031936.00001309
- The paper
- Bourbeau, J., & van der Palen, J. (2009). Promoting effective self-management programmes to improve COPD. European Respiratory Journal. https://doi.org/10.1183/09031936.00001309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.